Risk of COVID-19 on Diabetes Mellitus and Hypertension

The pandemic of coronavirus disease (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), is causing substantial morbidity and mortality. Older age and presence of diabetes mellitus, hypertension and obesity significantly increases the risk for hospitalization and death in COVID-19 patients. In this Perspective, informed by the studies on SARS-CoV-2, Middle East respiratory syndrome (MERS-CoV), and the current literature on SARS-CoV-2, we discuss potential mechanisms by which diabetes modulates the host-viral interactions and host-immune responses. We hope to highlight gaps in knowledge that require further studies pertinent to COVID-19 in patients with diabetes mellitus, hypertension and obesity.


Introduction
Coronaviruses (CoV) are enveloped viruses with a single stranded, positive-sense RNA genome known to cause respiratory infections in humans (Cui et al., 2019;Su et al., 2016). In general, in most immunocompetent individuals, human CoV infection leads to mild upper respiratory infection. However, two highly pathogenic CoV have resulted in outbreaks of severe acute respiratory syndrome (SARS) in 2003 in Guangdong province, China and Middle East respiratory syndrome (MERS) in Middle Eastern countries a decade later. SARS-CoV and MERS-CoV were identified to cause SARS and MERS, respectively [1,2,3].
In December 2019, a novel coronavirus, SARS-CoV-2, was identified as the pathogen causing coronavirus disease  in Wuhan, China [2,3]. On August 30, 2020, COVID-19 was declared a pandemic by the World Health Organization. As of August 30, 2020, there have been a total cases of coronaviruses of 25,252,662; 6,809,364 active cases, 6,748,068 (99%) in mild cases and 61,296 (1%) in serious or critical condition; 847,986 deaths and 17,595,312 recovered cases have been reported [4].
Individuals with diabetes mellitus (DM), hypertension and severe obesity (BMI 40 kg/m 2 ) are more likely to be infected and are at a higher risk for complications and death from COVID-19 [5,6,7,8,9].
Specialists and health care providers will be providing clinical care to many patients with COVID-19 in inpatient, outpatient, and telehealth settings. Increased awareness of the clinical features, pathophysiology, and potential mechanisms that increase the risk is needed to provide better care and spur new investigations, both basic and clinical, to better understand COVID-19 in patients with diabetes, hypertension and obesity [4,10].

Clinical Features and Natural Course of COVID-19
The median age of patients infected with SARS-CoV-2 is in the range of 47-56 years, men comprise more than half of the cases, the average incubation period is 5.2 days, and 98% of those who develop symptoms will do so within 11.5 days [11,12,14,15].
The clinical manifestations of COVID-19 vary and include the asymptomatic carrier status, acute respiratory disease (ARD), and pneumonia [16,17]. The prevalence of asymptomatic cases is significant (20 -86% of all infections) and are defined as individuals with positive viral nucleic acid tests, but without any COVID-19 symptoms [18,19,20] Transmission rates and respiratory viral load in asymptomatic carriers are similar to symptomatic patients [21,22], partially explaining the rapid spread of SARS-CoV-2. In addition to a laboratory-confirmed COVID-19 diagnosis, patients with ARD manifest with fever, fatigue, respiratory (cough, dyspnea) or gastrointestinal (nausea, diarrhea, vomiting) symptoms, and no significant abnormalities on chest imaging [22]. Patients with pneumonia have respiratory symptoms and positive findings in chest imaging. Severe pneumonia can present as acute respiratory distress syndrome (ARDS), leading to severe hypoxia, respiratory failure, multi organ failure, shock, and death [22,23].

The pathophysiology of SARS-CoV-2 Infection
The genetic sequence of SARS-CoV-2 showed more than 80% shared identity to SARS-CoV and 50% to the MERS-CoV, and both SARS-CoV and MERS-CoV originate in bats and infect humans and wild animals [24,25,26,27]. Cellular CoV entry is a complex process that involves receptor binding and proteolysis leading to virus-cell fusion. CoV is made up of four structural proteins: spike (S), membrane (M), nucleocapsid (N), and envelope (E) proteins. The S protein mediates receptor binding on the host cell membrane through the receptor-binding domain (RBD) in the S1 domain and membrane fusion through the S2 subunit [28,29].
Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for SARS-CoV and SARSCoV-2, in contrast to MERS-CoV, which utilizes dipeptidyl peptidase 4 (DPP4) as its cellular receptor [30,31] (Figure 1). This interaction thus determines host tropism and ultimately clearance of the virus. ACE2 is expressed in the upper respiratory system, type I and II alveolar epithelial cells in the lungs, the heart, endothelial cells, kidney tubular epithelium, enterocytes, and the pancreas [32,33,34,35,36]. After binding to ACE2, proximal serine proteases such as TMPRSS2 are involved in S protein priming and cleavage of the spike ( Figure  1).
Proteases such as Furin subsequently release the spike fusion peptide, and the cellular virus enters through an endosomal pathway [36,37]. The low pH and presence of proteases such as cathepsin-L characteristic of the endosomal microenvironment favor the delivery of SARS-CoV-2 genome into the cytosol where further viral replication leads to the formation of mature virions and subsequent spread. . The initial step in cellular entry of the virus is the binding of SARS-CoV-2 spike protein to cell surface angiotensin converting enzyme 2 (ACE2). Cellular proteases such as TMPRSS2 and furin are involved in priming of the S protein, which involves cleavage at the S1/S2 domains. This allows the fusion of the virus to the cell surface. Virions are taken up into endosomes, where SARS-CoV-2-S is cleaved and possibly activated by the pH-dependent cysteine protease cathepsin L. Once inside the cell, SARS-CoV-2 uses the endogenous cellular machinery to replicate itself. ACE catalyzes the conversion of angiotensin (Ang) I to the octapeptideAngII, whereas ACE2 converts AngII to Ang1-7. AngII through the activation of Ang II type 1a receptors induces vasoconstriction and proliferation, whereas Ang1-7 stimulates vasodilatation and suppresses cell growth [37].
Infected cells undergo apoptosis or necrosis and trigger inflammatory responses marked by the activation of pro-inflammatory cytokines or chemokines, which leads to the recruitment of inflammatory cells. CD4 T helper (Th1) cells regulate antigen presentation and immunity against intracellular pathogens such as CoV through interferon gamma (IFN-) production [39].
Lower T cell function relieves the inhibition on innate immune system leading to secretion of high amounts of inflammatory cytokines in what is known as a "cytokine storm" [41]. In fact, circulating levels of cytokines/chemokines [IL-6, tumor necrosis factor-(TNF)] and chemokines [CXC-chemokine ligand 10 (CXCL10) and CC-chemokine ligand 2 (CCL2)] involved in the cytokine storm syndrome are elevated and may play a role in SARSCoV-2-driven hyper inflammation leading to multi organ failure [41,42,43].

Potential Mechanisms that increase the Risk of COVID-19 in Diabetes Mellitus and Hypertension
It is now well recognized that older age and the presence of diabetes mellitus (DM), hypertension and severe obesity (BMI 40 kg/m 2 ) increase morbidity and mortality in patients with COVID-19 [44,45]. Considering the high prevalence of cardiovascular disease (CVD), obesity, and hypertension in patients with DM, it is unknown whether DM independently contributes to this increased risk. However, plasma glucose levels and DM are independent predictors for mortality and morbidity in patients with SARS [46]. Potential mechanisms that may increase the susceptibility for COVID-19 in patients with DM include [46]: (1) Higher affinity cellular binding and efficient virus entry, Augmented ACE2 expression in alveolar AT2 cells, myocardium, kidney, and pancreas may favor increased cellular binding of SARS-CoV-2 [47,48,49]. Increased expression of ACE2 has been demonstrated in the lung, kidney, heart, and pancreas in rodent models of DM [32,27]. Insulin administration attenuates ACE2 expression [32,29], while hypoglycemic agents such as glucagon-like peptide-1 (GLP-1) agonists (liraglutide) and thiazolidinediones (TZDs; pioglitazone), antihypertensives such as ACE inhibitors, and statins upregulate ACE2 [23,27,20]. Until recently, whether DM was causally linked to ACE2 expression levels in the lung in humans was unknown.
Using a phenome-wide Mendelian randomization study [48], explored diseases or traits that may be causally linked to increased ACE2 expression in the lung. Interestingly, they found that DM was causally associated with increased lung ACE2 expression. Circulating levels of furin, a cellular protease involved in facilitating viral entry by cleaving the S1 and S2 domain of the spike protein, are elevated in patients with DM [49]. These studies support the hypothesis that patients with DM are susceptible to SARS-CoV-2 infection. Indeed, a recent study reported that clearance of SARS-CoV-2 was delayed in patients with DM, a finding that needs to be confirmed in larger studies [50].
ACE catalyzes the conversion of the prohormone, angiotensin (Ang) I to the octapeptide, AngII), whereas ACE2 converts AngII to Ang1-7. AngII, through the activation of Ang II type 1a receptors induces vasoconstriction and proliferation, whereas Ang1-7 stimulates vasodilatation and suppresses cell growth (Figure 1). Increased ratio of pulmonary ACE/ACE2 activity as observed in patients with ARDS [28] favors AngII generation.
Once bound to ACE2, SARS CoV down regulates cellular expression of ACE2, and the unopposed action of AngII contributes to acute lung injury [39]. Binding to ACE2 alone does not lead to severe lung injury as is observed with other CoVs (NL63) [50,51].
Whether SARS-CoV-2 causes down regulation of pulmonary ACE2 is unknown. Nevertheless, there exists a potential for salutary, if not therapeutic, effects of Ang II receptor blockers, ACE inhibitors, TZDs, GLP-1 agonists, and statins in the setting of low ACE2 expression. Lacking further evidence of risk or benefit, the American College of Cardiology, the American Heart Association, and the American Society of Hypertension have recommended that patients should continue treatment with their usual antihypertensive therapy [52].
Diabetes mellitus inhibits neutrophil chemotaxis, phagocytosis, and intracellular killing of microbes. Impairments in adaptive immunity characterized by an initial delay in the activation of Th1 cell-mediated immunity and a late hyper-inflammatory response are often observed in patients with diabetes. In an elegant study, examined the effects of DM in a humanized mouse model of MERS-CoV infection on a high-fat diet [53,54,55].
Following MERS-CoV infection, the disease was more severe and prolonged in diabetic male mice and was characterized by alterations in CD4 T cell counts and abnormal cytokine responses (such as elevated IL17a). Consistent with this finding, in patients with COVID-19, peripheral counts of CD4 and CD8 T cells are low, but with a higher proportion of highly pro-inflammatory Th17 CD4 T cells, as well as elevated cytokine levels [56,57,58]. Thus, it is likely that patients with DM may have blunted anti-viral IFN responses, and the delayed activation of Th1/Th17 may contribute to accentuated inflammatory responses (Figure 2).

Conclusion
There is a paucity of data in the United States regarding comorbidities and COVID-19 outcomes and mechanisms that modulate viral pathogenesis. Certain racial groups such as African Americans, Hispanics, Asians, and Native Americans are highly prone to develop DM, and disparities in health care make these groups more vulnerable. Identification of clinical and biochemical parameters using multi-omics approaches that predict severity of the COVID-19 in DM, hypertension and obesity using large data sets is urgently needed. Studies in humanized ACE2 (hACE2) mice and non-human primates aimed at understanding how hyperglycemia, hyperinsulinemia, and hypoglycemic agents affect pathogenesis of COVID-19 and how DM and hypertension affects the efficacy of vaccines and antiviral investigational agents currently in trials are warranted. Finally, we need to develop novel ways to deliver care to our patients with DM and hypertension using telehealth, remote patient monitoring, and wearable technologies. As the global pandemic unfolds and rapidly spreads across the United States, social isolation measures will enable the transition, but there is an urgent need for basic and clinical investigations to address the many important and unanswered questions.